Polymyalgia Rheumatica and Giant Cell Arteritis in the Elderly

Chapter

Abstract

Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) occur almost exclusively in persons aged ³50 years. The prevalence in USA is 0.3% for PMR and 0.1% for GCA. GCA occurs in at least 15% of PMR patients. About 40% of GCA patients exhibit symptoms of PMR. PMR is characterized by sudden onset of shoulder and/or pelvic girdle pain with malaise and signs of inflammation. Typical symptoms for GCA are headache, swollen and tender temporal arteries, and jaw claudication. Ophthalmic complications such as anterior ischemic optic neuropathy, amaurosis fugax, or diplopia often occur in untreated disease. Large-vessel GCA particularly involves the proximal arm arteries. Symptoms may be less typical than in classic temporal arteritis. ESR and CRP are highly elevated. Magnetic resonance imaging (MRI) or ultrasound shows glenohumeral synovitis, subdeltoid bursitis, biceps tenosynovitis, hip synovitis, and/or trochanteric bursitis in PMR. Ultrasound and MRI scans ­display inflammatory wall swelling; ultrasound also detects stenoses and occlusions in acutely inflamed temporal arteries. Imaging is also a valuable tool for large-vessel GCA. Temporal artery histology displays mononuclear infiltrates, granulomas, and/or giant cells in acute temporal arteritis. Imaging may replace histology in experienced centers if ­findings are typical. Corticosteroids remain the mainstay of treatment. Starting doses are 15–25 mg/day of prednisone for PMR and 40–70 mg/day for GCA. Dose reduction should be consequent, always trying to reach the lowest effective dose. Methotrexate can be provided for those who need >10 mg/day of prednisone. Low-dose aspirin reduces the incidence of ophthalmic complications in acute disease.

Keywords

Giant cell arteritis Polymyalgia rheumatica Ultrasonography Magnetic resonance imaging Histology Treatment 

References

  1. 1.
    Lawrence RC, Felson DT, Helmick CG, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum. 2008;58:26–35.PubMedCrossRefGoogle Scholar
  2. 2.
    Schmidt WA. Takayasu and temporal arteritis. Front Neurol Neurosci. 2006;21:96–104.PubMedCrossRefGoogle Scholar
  3. 3.
    Dasgupta B, Cimmino MA, Maradit-Kremers H, et al. European League Against Rheumatism – Ameican College of Rheumatology classification criteria for polymyalgia rheumatica. Ann Rheum Dis (in press).PubMedGoogle Scholar
  4. 4.
    Hunder GG, Bloch DA, Michel BA, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum. 1990;33:1122–8.PubMedCrossRefGoogle Scholar
  5. 5.
    Smetana GW, Shmerling RH. Does this patient have temporal arteritis? JAMA. 2002;287:92–101.PubMedCrossRefGoogle Scholar
  6. 6.
    Schmidt WA, Gromnica-Ihle E. What is the best approach to diagnose large-vessel vasculitis? Best Pract Res Clin Rheumatol. 2005;19:223–42.PubMedCrossRefGoogle Scholar
  7. 7.
    Schmidt WA. Current diagnosis and treatment of temporal arteritis. Curr Treat Options Cardiovasc Med. 2006;8:145–51.PubMedCrossRefGoogle Scholar
  8. 8.
    Salvarani C, Hunder GG. Giant cell arteritis with low erythrocyte sedimentation rate: frequency of occurrence in a population-based study. Arthritis Rheum. 2002;57:692–3.Google Scholar
  9. 9.
    Blockmans D, De Ceuninck L, Vanderschueren S, et al. Repetitive 18-fluorodeoxyglucose positron emission tomography in isolated polymyalgia rheumatica: a prospective study in 35 patients. Rheumatology. 2007;46:672–7.PubMedCrossRefGoogle Scholar
  10. 10.
    Cantini F, Salvarani C, Niccoli L, et al. Fat suppression magnetic resonance imaging in shoulders of patients with polymyalgia rheumatica. J Rheumatol. 2004;31:120–4.PubMedGoogle Scholar
  11. 11.
    Cantini F, Niccoli L, Nannini C, et al. Inflammatory changes of hip synovial structures in polymyalgia rheumatica. Clin Exp Rheumatol. 2005;23:462–8.PubMedGoogle Scholar
  12. 12.
    Salvarani C, Barozzi L, Cantini F, et al. Cervical interspinous bursitis in active polymyalgia rheumatica. Ann Rheum Dis. 2008;67:758–61.PubMedCrossRefGoogle Scholar
  13. 13.
    Cantini F, Salvarani C, Olivieri I, et al. Shoulder ultrasonography in the diagnosis of polymyalgia rheumatica: a case–control study. J Rheumatol. 2001;28:1049–55.PubMedGoogle Scholar
  14. 14.
    Frediani B, Falsetti P, Storri L. Evidence for synovitis in active polymyalgia rheumatica: sonographic study in a large series of patients. J Rheumatol. 2002;29:123–30.PubMedGoogle Scholar
  15. 15.
    Scheel AK, Schmidt WA, Hermann KG, et al. Interobserver reliability of rheumatologists performing musculoskeletal ultrasonography: results from a EULAR “train the trainers” course. Ann Rheum Dis. 2005;64:1043–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Bruyn GA, Naredo E, Möller I, et al. Reliability of ultrasonography in detecting shoulder disease in patients with rheumatoid arthritis. Ann Rheum Dis. 2009;69:357–61.CrossRefGoogle Scholar
  17. 17.
    Schmidt WA, Kraft HE, Vorpahl K, Völker L, Gromnica-Ihle EJ. Color duplex ultrasonography in the diagnosis of temporal arteritis. N Engl J Med. 1997;337:1336–42.PubMedCrossRefGoogle Scholar
  18. 18.
    Bley TA, Wieben O, Uhl M, Thiel J, Schmidt D, Langer M. High-resolution MRI in giant cell arteritis: imaging of the wall of the superficial temporal artery. AJR Am J Roentgenol. 2005;184:283–7.PubMedGoogle Scholar
  19. 19.
    Karassa FB, Matsagas MI, Schmidt WA, Ioannidis JP. Diagnostic performance of ultrasonography for giant-cell arteritis: a meta-analysis. Ann Intern Med. 2005;142:359–69.PubMedGoogle Scholar
  20. 20.
    Schmidt WA, Gromnica-Ihle E. Duplex ultrasonography in temporal arteritis. Ann Intern Med. 2003;138:609.PubMedGoogle Scholar
  21. 21.
    Bley TA, Uhl M, Carew J, et al. Diagnostic value of high-resolution MR imaging in giant cell arteritis. AJNR Am J Neuroradiol. 2007;28:1722–7.PubMedCrossRefGoogle Scholar
  22. 22.
    Schmidt WA, Blockmans D. Use of ultrasonography and positron emission tomography in the diagnosis and assessment of large-vessel vasculitis. Curr Opin Rheumatol. 2005;17:9–15.PubMedCrossRefGoogle Scholar
  23. 23.
    Schmidt WA. Use of imaging studies in the diagnosis of vasculitis. Curr Rheumatol Rep. 2004;6:203–11.PubMedCrossRefGoogle Scholar
  24. 24.
    Schmidt WA, Wagner AD. Role of imaging in diagnosis of and differentiation between vasculitides. Fut Rheumatol. 2006;1:627–34.CrossRefGoogle Scholar
  25. 25.
    Schmidt WA. The role of color and power Doppler sonography in rheumatology. Nat Clin Pract Rheumatol. 2007;3:35–42.PubMedCrossRefGoogle Scholar
  26. 26.
    Pipitone N, Versari A, Salvarani C. Role of imaging studies in the diagnosis and follow-up of large-vessel vasculitis: an update. Rheumatology. 2008;47:403–8.PubMedCrossRefGoogle Scholar
  27. 27.
    Stanson AW. Imaging findings in extracranial (giant cell) temporal arteritis. Clin Exp Rheumatol. 2000;18(4 Suppl 20):S43–8.PubMedGoogle Scholar
  28. 28.
    Blockmans D, de Ceuninck L, Vanderschueren S, Knockaert D, Mortelmans L, Bobbaers H. Repetitive 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a prospective study of 35 patients. Arthritis Rheum. 2006;55:131–7.PubMedCrossRefGoogle Scholar
  29. 29.
    Hautzel H, Sander O, Heinzel A, Schneider M, Müller HW. Assessment of large-vessel involvement in giant cell arteritis with 18F-FDG PET: Introducing an ROC-analysis-based cutoff ratio. J Nucl Med. 2008;49:1107–13.PubMedCrossRefGoogle Scholar
  30. 30.
    Mahr A, Saba M, Kambouchner M, et al. Temporal artery biopsy for diagnosing giant cell arteritis: the longer, the better? Ann Rheum Dis. 2006;65:826–8.PubMedCrossRefGoogle Scholar
  31. 31.
    Sharma NS, Ooi JL, McGarity BH, Vollmer-Conna U, McCluskey P. The length of superficial temporal artery biopsies. ANZ J Surg. 2007;77:437–9.PubMedCrossRefGoogle Scholar
  32. 32.
    Narváez J, Bernad B, Roig-Vilaseca D, et al. Influence of previous corticosteroid therapy on temporal artery biopsy yield in giant cell arteritis. Semin Arthritis Rheum. 2007;37:13–9.PubMedCrossRefGoogle Scholar
  33. 33.
    Makkuni D, Bharadwaj A, Wolfe K, Payne S, Hutchings A, Dasgupta B. Is intimal hyperplasia a marker of neuro-ophthalmic complications of giant cell arteritis? Rheumatology. 2008;47:488–90.PubMedCrossRefGoogle Scholar
  34. 34.
    Chatelain D, Duhaut P, Schmidt J, et al. Pathological features of temporal arteries in patients with giant cell arteritis presenting with permanent visual loss. Ann Rheum Dis. 2009;68:84–8.PubMedCrossRefGoogle Scholar
  35. 35.
    Brack A, Martinez-Taboada V, Stanson A, Goronzy JJ, Weyand CM. Disease pattern in cranial and large-vessel giant cell arteritis. Arthritis Rheum. 1999;42:311–7.PubMedCrossRefGoogle Scholar
  36. 36.
    Schmidt WA, Seifert A, Gromnica-Ihle E, Krause A, Natusch A. Ultrasound of proximal upper extremity arteries to increase the diagnostic yield in large-vessel giant cell arteritis. Rheumatology. 2008;47:96–101.PubMedCrossRefGoogle Scholar
  37. 37.
    Schmidt WA, Moll A, Seifert A, Schicke B, Gromnica-Ihle E, Krause A. Prognosis of large-vessel giant cell arteritis. Rheumatology. 2008;47:1406–8.PubMedCrossRefGoogle Scholar
  38. 38.
    Evans JM, O’Fallon WM, Hunder GG. Increased incidence of aortic aneurysm and dissection in giant cell (temporal) arteritis. A population-based study. Ann Intern Med. 1995;122:502–7.PubMedGoogle Scholar
  39. 39.
    García-Martínez A, Hernández-Rodríguez J, Arguis P, et al. Development of aortic aneurysm/dilatation during the follow-up of patients with giant cell arteritis: a cross-sectional screening of fifty-four prospectively followed patients. Arthritis Rheum. 2008;59:422–30.PubMedCrossRefGoogle Scholar
  40. 40.
    Delecoeuillerie G, Joly P, Cohen de Lara A, Paolaggi JB. Polymyalgia rheumatica and temporal arteritis: a retrospective analysis of prognostic features and different corticosteroid regimens (11 year survey of 210 patients). Ann Rheum Dis. 1988;47:733–9.PubMedCrossRefGoogle Scholar
  41. 41.
    Jover JA, Hernandez-Garcia C, Morado IC, Vargas E, Banares A, Fernandez-Gutierrez B. Combined treatment of giant-cell arteritis with methotrexate and prednisone: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2001;134:106–14.PubMedGoogle Scholar
  42. 42.
    Hoffman GS, Cid MC, Hellmann DB, et al. A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum. 2002;46:1309–18.PubMedCrossRefGoogle Scholar
  43. 43.
    Caporali R, Cimmino MA, Ferraccioli G, et al. Prednisone plus methotrexate for polymyalgia rheumatica: a randomized double-blind, placebo-controlled trial. Ann Intern Med. 2004;141:493–500.PubMedGoogle Scholar
  44. 44.
    Hoffman GS, Cid MC, Rendt-Zagar KE, et al. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med. 2007;146:621–30.PubMedGoogle Scholar
  45. 45.
    Salvarani C, Macchioni P, Manzini C, et al. Infliximab plus prednisone or placebo plus prednisone for the initial treatment of polymyalgia rheumatica: a randomized trial. Ann Intern Med. 2007;146:631–9.PubMedGoogle Scholar
  46. 46.
    Nesher G, Berkun Y, Mates M, Baras M, Rubinow A, Sonnenblick M. Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis. Arthritis Rheum. 2004;50:1332–7.PubMedCrossRefGoogle Scholar
  47. 47.
    Lee MS, Smith SD, Galor A, Hoffman GS. Antiplatelet and anticoagulant therapy in patients with giant cell arteritis. Arthritis Rheum. 2006;54:3306–9.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Medical Center for Rheumatology Berlin BuchImmanuel Krankenhaus BerlinBerlinGermany

Personalised recommendations